Evaluation of serum levels of selected cytokine receptors in adult B-cell precursor acute lymphoblastic leukemia and their association with prognostic factors and survival
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-3.16548Keywords:
acute lymphoblastic leukemia, cytokine, prognosis, sIL-2Rα, soluble cytokine receptor, survivalAbstract
Summary. Aim: To evaluate serum levels of selected cytokine receptors in B-cell precursor acute lymphoblastic leukemia (B-ALL) and their association with acknowledged prognostic factors, relapse-free survival (RFS) and overall survival (OS). Materials and Methods: A total of 42 de novo adult B-ALL patients, 19 BCR/ABL positive, were included in this study. Soluble receptor α for IL-2 (sIL-2Rα), soluble receptor for IL-6 (sIL-6R), soluble receptor for TNF-α type I and II (sTNFR-1, sTNFR-2) and matrix metalloproteinase-9 (MMP-9) were measured by biochip array technology at diagnosis and in complete remission (CR). Results: At diagnosis of B-ALL, we found significantly higher levels of sIL-2Rα, sIL-6R, sTNFR-1, sTNFR-2 and significantly lower levels MMP-9 in comparison with CR (p < 0.001 in all cases). BCR/ABL positive patients had higher levels of sIL-2Rα at diagnosis (r = 0.484; p = 0.014). Serum levels of evaluated cytokines were not associated with achievement of CR after one cycle of induction therapy, RFS or OS. Conclusion: Serum levels of all evaluated cytokines are significantly altered in newly diagnosed B-ALL reflecting activity of the disease. No significant correlations with response to first induction therapy, RFS or OS were found. Further studies with a longer follow-up will be needed.
References
Kurzrock R. Cytokine deregulation in cancer. Biomed Pharmacother 2001; 55: 543–7. https://doi.org/10.1016/s0753-3322(01)00140-8.
Kupsa T, Horacek JM, Jebavy L. The role of adhesion molecules in acute myeloid leukemia and (hemato)oncology: a systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159: 1–11. https://doi.org/10.5507/bp.2014.049.
Showalter A, Limaye A, Oyer JL, et al. Cytokines in immunogenic cell death: Applications for cancer immunotherapy. Cytokine 2017; 97: 123–32. https://doi.org/10.1016/j.cyto.2017.05.024.
Stevens AM, Miller JM, Munoz JO, et al. Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Adv 2017; 1: 1387–97. https://doi.org/10.1182/bloodadvances.2017007856.
Höpken UE, Rehm A. Targeting the tumor microenvironment of leukemia and lymphoma. Trends Cancer 2019; 5: 351–64. https://doi.org/10.1016/j.trecan.2019.05.001.
Vinante F, Rigo A, Tecchio C, et al. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome. Br J Haematol 1998; 102: 1025–34. https://doi.org/10.1046/j.1365-2141.1998.00872.x.
Kornblau SM, McCue D, Singh N, et al. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010; 116: 4251–61. https://doi.org/10.1182/blood-2010-01-262071.
Horacek JM, Kupsa T, Vasatova M, et al. Serum cytokine and adhesion molecule profile differs in newly diagnosed acute myeloid and lymphoblastic leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159: 299–301. https://doi.org/10.5507/bp.2014.051.
Kupsa T, Vanek J, Zak P, et al. Serum levels of selected cytokines and soluble adhesion molecules in acute myeloid leukemia: Soluble receptor for interleukin-2 predicts overall survival. Cytokine 2020; 128: 155005. https://doi.org/10.1016/j.cyto.2020.155005.
Kupsa T, Horacek JM, Jebavy L. The role of cytokines in acute myeloid leukemia: A systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156: 291–301. https://doi.org/10.5507/bp.2012.108.
Saluk J, Hoppensteadt D, Syed D, et al. Biomarker profiling of plasma samples utilizing Randox biochip array technology. Int Angiol 2017; 36: 499–504. https://doi.org/10.23736/S0392-9590.17.03854-8.
Horacek JM, Kupsa T, Vasatova M, et al. Evaluation of serum levels of multiple cytokines and adhesion molecules in patients with newly diagnosed acute lymphoblastic leukemia using biochip array technology. Exp Oncol 2013; 35: 229–30. PMID: 24084464.
Kupsa T, Vasatova M, Karesova I, et al. Baseline serum levels of multiple cytokines and adhesion molecules in patients with acute myeloid leukemia: results of a pivotal trial. Exp Oncol 2014; 36: 252–7. PMID: 25537219.
Gupta M, Stenson M, O’Byrne M, et al. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma. Ann Oncol 2016; 27: 165–72. https://doi.org/10.1093/annonc/mdv486.
Almeida RDS, Ramos AML, Luna CF, et al. Cytokines and soluble HLA-G levels in bone marrow stroma and their association with the survival rate of patients exhibiting childhood T-cell acute lymphoblastic leukemia. Cytokine 2018; 102: 94–101. https://doi.org/10.1016/j.cyto.2017.07.014.
Moorman AV. New and emerging prognostic and predic¬tive genetic biomarkers in B-cell precursor acute lympho¬blastic leukemia. Haematologica 2016; 101: 407–16. https://doi.org/10.3324/haematol.2015.141101. 17. Abou Dalle I, Jabbour E, Short NJ, et al. Treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Treat Options Oncol 2019; 20: 4. https://doi.org/10.1007/s11864-019-0603-z.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
